探索和检测与宫颈癌患者生存和死亡率相关的预测因素:一项10年回顾性研究

IF 2.5 Q2 MULTIDISCIPLINARY SCIENCES
Shaba Muneeha, Raushan Kumar Chaudhary, Vijith Vittal Shetty, Soumya Patil, Uday Venkat Mateti
{"title":"探索和检测与宫颈癌患者生存和死亡率相关的预测因素:一项10年回顾性研究","authors":"Shaba Muneeha,&nbsp;Raushan Kumar Chaudhary,&nbsp;Vijith Vittal Shetty,&nbsp;Soumya Patil,&nbsp;Uday Venkat Mateti","doi":"10.1186/s43088-025-00602-4","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><p>Cervical cancer is the 4th most prevalent cancer among females globally. In India, approximately 123,907 women are diagnosed with cervical cancer every year, leading to 77,348 deaths annually. However, Indian healthcare system lacks the sufficient information regarding the factors influencing survival and mortality among cervical cancer patients at regional levels. Thus, we aimed to identify the predictors associated with survival outcomes and mortality rates among cervical cancer.</p><h3>Methods</h3><p>A retrospective cohort study was conducted over 8 months at a tertiary care hospital where 10-year (January 2013–December 2022) data of cervical cancer patients were analyzed from medical record department (MRD). Telephonic interviews were carried out with patients or patient parties to know the survival status of patients. The data was analyzed using descriptive statistics, Kaplan–Meier curve, log-rank test and Cox regression.</p><h3>Results</h3><p>Out of 330 cervical cancer patients, majority (64.24%) were &gt; 50 years of age followed by 35.76% were &lt; 50 years. Most of the patients had abnormal body mass index (BMI) (46.96%), postmenopausal stage (75.76%), stage II cancer (43.03%), histologically poorly differentiated grade (47.88%) and squamous cell carcinoma (87.88%), with radiation plus chemotherapy being popular treatment choice (48.79%) and with the overall mean age of 56 years. Age, BMI, menopause, stage of cancer, histological grades and types of treatment were found to be significant predictors (<i>p</i> &lt; 0.05) of survival among cervical cancer patients. Using cox regression analysis, advanced age (age &gt; 50 years: hazard ratio (HR): 1.82), underweight (BMI &lt; 18.5: HR:1), postmenopause (HR:1), advanced stage of cervical cancer (Stage I, Stage II, Stage III, Stage IV: HR:1, HR:2.78, HR:10.08, HR:20.81), poorly differentiated cervical cancer (HR:1.70), radiation therapy (HR:4.86), chemotherapy (HR:6.55) or chemoradiation therapy (HR:3.31) and surgery plus chemotherapy (HR: 4.55) were identified to be significant predictors of mortality among cervical cancer patients.</p><h3>Conclusion</h3><p>We conclude that the 5- and 10-year survival rates for cervical cancer patients were found to be 51.2% and 42.9%, respectively. Advanced age, underweight, postmenopausal status, advanced cancer stage, poor cancer cell differentiation and chemotherapy-based treatment were significant predictor of mortality and vice-versa for survival which might guide clinicians and policymakers in making informed clinical decisions to combat cervical cancer.</p></div>","PeriodicalId":481,"journal":{"name":"Beni-Suef University Journal of Basic and Applied Sciences","volume":"14 1","pages":""},"PeriodicalIF":2.5000,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://bjbas.springeropen.com/counter/pdf/10.1186/s43088-025-00602-4","citationCount":"0","resultStr":"{\"title\":\"Exploring and detecting predictors associated with survival and mortality of cervical cancer patients: a 10-year retrospective study\",\"authors\":\"Shaba Muneeha,&nbsp;Raushan Kumar Chaudhary,&nbsp;Vijith Vittal Shetty,&nbsp;Soumya Patil,&nbsp;Uday Venkat Mateti\",\"doi\":\"10.1186/s43088-025-00602-4\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><p>Cervical cancer is the 4th most prevalent cancer among females globally. In India, approximately 123,907 women are diagnosed with cervical cancer every year, leading to 77,348 deaths annually. However, Indian healthcare system lacks the sufficient information regarding the factors influencing survival and mortality among cervical cancer patients at regional levels. Thus, we aimed to identify the predictors associated with survival outcomes and mortality rates among cervical cancer.</p><h3>Methods</h3><p>A retrospective cohort study was conducted over 8 months at a tertiary care hospital where 10-year (January 2013–December 2022) data of cervical cancer patients were analyzed from medical record department (MRD). Telephonic interviews were carried out with patients or patient parties to know the survival status of patients. The data was analyzed using descriptive statistics, Kaplan–Meier curve, log-rank test and Cox regression.</p><h3>Results</h3><p>Out of 330 cervical cancer patients, majority (64.24%) were &gt; 50 years of age followed by 35.76% were &lt; 50 years. Most of the patients had abnormal body mass index (BMI) (46.96%), postmenopausal stage (75.76%), stage II cancer (43.03%), histologically poorly differentiated grade (47.88%) and squamous cell carcinoma (87.88%), with radiation plus chemotherapy being popular treatment choice (48.79%) and with the overall mean age of 56 years. Age, BMI, menopause, stage of cancer, histological grades and types of treatment were found to be significant predictors (<i>p</i> &lt; 0.05) of survival among cervical cancer patients. Using cox regression analysis, advanced age (age &gt; 50 years: hazard ratio (HR): 1.82), underweight (BMI &lt; 18.5: HR:1), postmenopause (HR:1), advanced stage of cervical cancer (Stage I, Stage II, Stage III, Stage IV: HR:1, HR:2.78, HR:10.08, HR:20.81), poorly differentiated cervical cancer (HR:1.70), radiation therapy (HR:4.86), chemotherapy (HR:6.55) or chemoradiation therapy (HR:3.31) and surgery plus chemotherapy (HR: 4.55) were identified to be significant predictors of mortality among cervical cancer patients.</p><h3>Conclusion</h3><p>We conclude that the 5- and 10-year survival rates for cervical cancer patients were found to be 51.2% and 42.9%, respectively. Advanced age, underweight, postmenopausal status, advanced cancer stage, poor cancer cell differentiation and chemotherapy-based treatment were significant predictor of mortality and vice-versa for survival which might guide clinicians and policymakers in making informed clinical decisions to combat cervical cancer.</p></div>\",\"PeriodicalId\":481,\"journal\":{\"name\":\"Beni-Suef University Journal of Basic and Applied Sciences\",\"volume\":\"14 1\",\"pages\":\"\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2025-02-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://bjbas.springeropen.com/counter/pdf/10.1186/s43088-025-00602-4\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Beni-Suef University Journal of Basic and Applied Sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://link.springer.com/article/10.1186/s43088-025-00602-4\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"MULTIDISCIPLINARY SCIENCES\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Beni-Suef University Journal of Basic and Applied Sciences","FirstCategoryId":"1085","ListUrlMain":"https://link.springer.com/article/10.1186/s43088-025-00602-4","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MULTIDISCIPLINARY SCIENCES","Score":null,"Total":0}
引用次数: 0

摘要

宫颈癌是全球第四大最常见的女性癌症。在印度,每年约有123 907名妇女被诊断患有宫颈癌,导致77 348人死亡。然而,印度的医疗保健系统缺乏足够的信息,关于影响地区宫颈癌患者生存和死亡的因素。因此,我们的目的是确定与宫颈癌生存结局和死亡率相关的预测因素。方法对某三级医院10年(2013年1月- 2022年12月)宫颈癌患者病案科(MRD)资料进行回顾性队列研究,历时8个月。对患者或患者当事人进行电话访谈,了解患者的生存状况。采用描述性统计、Kaplan-Meier曲线、log-rank检验和Cox回归对数据进行分析。结果330例宫颈癌患者中,50岁占64.24%,50岁占35.76%;大多数患者体重指数(BMI)异常(46.96%),绝经后分期(75.76%),II期癌症(43.03%),组织学低分化级别(47.88%)和鳞状细胞癌(87.88%),放疗加化疗是主要的治疗选择(48.79%),总体平均年龄56岁。年龄、BMI、绝经期、癌症分期、组织学分级和治疗方式是宫颈癌患者生存的显著预测因子(p < 0.05)。采用cox回归分析,高龄(年龄>; 50岁:风险比(HR): 1.82)、体重过轻(BMI <; 18.5:风险比:1)、绝经后(HR:1)、晚期宫颈癌(I期、II期、III期、IV期:风险比:1、风险比:2.78、风险比:10.08、风险比:20.81)、低分化宫颈癌(HR:1.70)、放疗(HR:4.86)、化疗(HR:6.55)或放化疗(HR:3.31)、手术加化疗(HR:4.55)被认为是宫颈癌患者死亡率的重要预测因素。结论宫颈癌患者5年和10年生存率分别为51.2%和42.9%。高龄、体重不足、绝经后状态、癌症晚期、癌细胞分化差和基于化疗的治疗是死亡率的重要预测因子,反之亦然,这可能指导临床医生和决策者做出明智的临床决策,以对抗宫颈癌。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Exploring and detecting predictors associated with survival and mortality of cervical cancer patients: a 10-year retrospective study

Background

Cervical cancer is the 4th most prevalent cancer among females globally. In India, approximately 123,907 women are diagnosed with cervical cancer every year, leading to 77,348 deaths annually. However, Indian healthcare system lacks the sufficient information regarding the factors influencing survival and mortality among cervical cancer patients at regional levels. Thus, we aimed to identify the predictors associated with survival outcomes and mortality rates among cervical cancer.

Methods

A retrospective cohort study was conducted over 8 months at a tertiary care hospital where 10-year (January 2013–December 2022) data of cervical cancer patients were analyzed from medical record department (MRD). Telephonic interviews were carried out with patients or patient parties to know the survival status of patients. The data was analyzed using descriptive statistics, Kaplan–Meier curve, log-rank test and Cox regression.

Results

Out of 330 cervical cancer patients, majority (64.24%) were > 50 years of age followed by 35.76% were < 50 years. Most of the patients had abnormal body mass index (BMI) (46.96%), postmenopausal stage (75.76%), stage II cancer (43.03%), histologically poorly differentiated grade (47.88%) and squamous cell carcinoma (87.88%), with radiation plus chemotherapy being popular treatment choice (48.79%) and with the overall mean age of 56 years. Age, BMI, menopause, stage of cancer, histological grades and types of treatment were found to be significant predictors (p < 0.05) of survival among cervical cancer patients. Using cox regression analysis, advanced age (age > 50 years: hazard ratio (HR): 1.82), underweight (BMI < 18.5: HR:1), postmenopause (HR:1), advanced stage of cervical cancer (Stage I, Stage II, Stage III, Stage IV: HR:1, HR:2.78, HR:10.08, HR:20.81), poorly differentiated cervical cancer (HR:1.70), radiation therapy (HR:4.86), chemotherapy (HR:6.55) or chemoradiation therapy (HR:3.31) and surgery plus chemotherapy (HR: 4.55) were identified to be significant predictors of mortality among cervical cancer patients.

Conclusion

We conclude that the 5- and 10-year survival rates for cervical cancer patients were found to be 51.2% and 42.9%, respectively. Advanced age, underweight, postmenopausal status, advanced cancer stage, poor cancer cell differentiation and chemotherapy-based treatment were significant predictor of mortality and vice-versa for survival which might guide clinicians and policymakers in making informed clinical decisions to combat cervical cancer.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
2.60
自引率
0.00%
发文量
0
期刊介绍: Beni-Suef University Journal of Basic and Applied Sciences (BJBAS) is a peer-reviewed, open-access journal. This journal welcomes submissions of original research, literature reviews, and editorials in its respected fields of fundamental science, applied science (with a particular focus on the fields of applied nanotechnology and biotechnology), medical sciences, pharmaceutical sciences, and engineering. The multidisciplinary aspects of the journal encourage global collaboration between researchers in multiple fields and provide cross-disciplinary dissemination of findings.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信